Overview

Treatment of Refractory Chronic Cough With PA101

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, 2-period crossover, 2-cohort study in adult patients with refractory chronic cough. The purpose of the study is to assess the efficacy and safety of inhaled PA101 delivered via eFlow high efficiency nebulizer for treating refractory chronic cough.
Phase:
Phase 2
Details
Lead Sponsor:
Patara Pharma